Business Description
Gubra AS
ISIN : DK0062266474
Total Employee Number:
269Compare
Compare
Traded in other countries / regions
GUBRA.DenmarkPI3.GermanyGUBRAc.UK IPO Date
2023-04-11Description
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.08 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.05 | |||||
Interest Coverage | 316.7 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 27.81 | |||||
Beneish M-Score | 4.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 135.9 | |||||
3-Year EBITDA Growth Rate | 428.4 | |||||
3-Year EPS without NRI Growth Rate | 617 | |||||
3-Year FCF Growth Rate | 448.6 | |||||
3-Year Book Growth Rate | 119.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.74 | |||||
9-Day RSI | 37.03 | |||||
14-Day RSI | 41.78 | |||||
3-1 Month Momentum % | -4.64 | |||||
6-1 Month Momentum % | -32.51 | |||||
12-1 Month Momentum % | -33.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.63 | |||||
Quick Ratio | 13.63 | |||||
Cash Ratio | 12.73 | |||||
Days Sales Outstanding | 4.83 | |||||
Days Payable | 137.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.04 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.96 | |||||
Operating Margin % | 81.54 | |||||
Net Margin % | 64.11 | |||||
EBITDA Margin % | 81.97 | |||||
FCF Margin % | 64.24 | |||||
OCF Margin % | 64.97 | |||||
ROE % | 180.38 | |||||
ROA % | 104.74 | |||||
ROIC % | 771.7 | |||||
3-Year ROIIC % | 2935.97 | |||||
ROC (Joel Greenblatt) % | 1853.92 | |||||
ROCE % | 211.84 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.14 | |||||
Forward PE Ratio | 54.75 | |||||
PE Ratio without NRI | 3.14 | |||||
Price-to-Owner-Earnings | 2.46 | |||||
PS Ratio | 2.01 | |||||
PB Ratio | 4.59 | |||||
Price-to-Tangible-Book | 4.64 | |||||
Price-to-Free-Cash-Flow | 3.13 | |||||
Price-to-Operating-Cash-Flow | 3.1 | |||||
EV-to-EBIT | 1.99 | |||||
EV-to-EBITDA | 1.99 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-FCF | 2.55 | |||||
Price-to-GF-Value | 0.11 | |||||
Price-to-Graham-Number | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 5.33 | |||||
| Price-to-Net-Cash | 5.78 | |||||
Earnings Yield (Greenblatt) % | 50.25 | |||||
FCF Yield % | 32.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gubra AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 353.428 | ||
| EPS (TTM) (€) | 13.767 | ||
| Beta | 0.1777 | ||
| 3-Year Sharpe Ratio | 0.83 | ||
| 3-Year Sortino Ratio | 2.1 | ||
| Volatility % | 54.25 | ||
| 14-Day RSI | 41.78 | ||
| 14-Day ATR (€) | 1.895015 | ||
| 20-Day SMA (€) | 45.612 | ||
| 12-1 Month Momentum % | -33.24 | ||
| 52-Week Range (€) | 41.84 - 74.1 | ||
| Shares Outstanding (Mil) | 16.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gubra AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gubra AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 52 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 52 days | ||
| General meeting for 2026 | 2026-03-26 10:00 | 48.02 (-1.32%) | ||
| Annual report for 2025 | 2026-02-27 | 45.32 (+4.42%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-21 10:00 | 47.70 (+1.97%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 47.70 (+1.97%) | ||
| DKK 61.200000 Cash Dividend | 2025-06-30 | 71.15 (+2.15%) | ||
| General meeting for 2025 | 2025-04-03 10:00 | 56.80 (-8.39%) | ||
| Annual report for 2024 | 2025-02-28 | 86.00 (+0.70%) | ||
| Second quarter earnings conference call for 2024 | 2024-08-22 10:00 | 83.00 (+1.22%) |
Show
Entries
Gubra AS Frequently Asked Questions
What is Gubra AS(STU:PI3)'s stock price today?
The current price of STU:PI3 is €43.04. The 52 week high of STU:PI3 is €74.10 and 52 week low is €41.84.
When is next earnings date of Gubra AS(STU:PI3)?
The next earnings date of Gubra AS(STU:PI3) is 2026-08-20.
Does Gubra AS(STU:PI3) pay dividends? If so, how much?
Gubra AS(STU:PI3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Gubra AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers